This study is being done to determine how well the study drug, BGB-290, gets into the brain tumor and to confirm if we can continuously and safely give BGB-290 and temozolomide as a combination treatment after surgery. We are testing a dose of temozolomide once a day combined with the study drug twice a day for a 28-day cycle. We want to determine if this combination treatment can shrink or lower the chance of the brain cancer tumor growing. It is possible that a lower dose of temozolomide will result in less side effects associated with BGB290 in combination. We are also conducting this study to find out if this approach is better or worse than the usual approach, or the standard of care, for your brain cancer.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research, Gliomas
• Age: 99 years or below
• Gender: All